Where The Money Is: Armed With Pharma Cash, VenBio Seeks Pharma Customers
This article was originally published in Start Up
Executive Summary
With $200 million under management and its first investment in the books, venBio is a new pharma-centric venture fund built for these strange times, when big drug companies have all the cash, all the leverage, and an insatiable need for new products.